Amgen
Search results
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite ® technologies, such as VelocImmune ®, which uses unique genetically humanized mice to produce optimized fully human antibodies, as well as bispecific and costimulatory antibodies. Our novel and patented “Trap” fusion ...
Visit Regeneron.co.jp Visit our global site Continue to Regeneron.com Cancel The site you are about to visit may not be intended for an audience in your location.
The companies made a shared commitment to making the antibody combination available to COVID-19 patients around the globe and to supporting access in low- and lower-middle-income countries through drug donations to be made in partnership with public health organizations.
2 days ago · The Investor Relations website contains information about Regeneron Pharmaceuticals Inc.'s business for stockholders, potential investors, and financial analysts.
5 days ago · You are now leaving Regeneron.com to visit another Regeneron pharmaceuticals website.
FASTR is a quantitative cell-surface display technology that enables the use of flow cytometry to select eukaryotic cells that secrete the highest levels of recombinant therapeutic proteins. NICE enables the control of the expression of secreted, recombinant therapeutic proteins in eukaryotic cells.
Regeneron | 445,429 followers on LinkedIn. At Regeneron we believe that when the right idea finds the right team, powerful change is possible.
